This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mulinari, R. A. Articles by Gavras, H. Search for Related Content PubMed PubMed Citation Articles by Mulinari, R. A. Articles by Gavras, H.

Circulation, Vol 81, 308-311, Copyright © 1990 by American Heart Association

ARTICLES

Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction

RA Mulinari, I Gavras, YX Wang, R Franco and H Gavras
Department of Medicine, Boston University School of Medicine, MA 02118.

These experiments assessed the hemodynamic and aquaretic effects of an arginine vasopressin (AVP) antagonist with dual V1V2-receptor inhibiting properties in rats with congestive heart failure resulting from ischemic cardiomyopathy. The compound d(CH2)5-D-Tyr(Et)VAVP was used in these studies. Rats with limited or extensive myocardial infarcts (i.e., with less than 50% or greater than 66% necrosis of the left ventricular wall, respectively, induced by left coronary ligation) and sham-operated controls received the AVP antagonist (100 micrograms/kg i.v.) 4 weeks later. This agent produced an 18% increase in cardiac output (p less than 0.05) and 13% decrease in systemic vascular resistance in the severely damaged rats, both changes being significantly different from those seen in the normal controls or the rats with limited infarcts. All animals exhibited increases in urinary output of 4-10-fold over baseline. We conclude that the hemodynamic and renal effects of this agent are beneficial in animals with left ventricular dysfunction.

This article has been cited by other articles:

				M. Naitoh, J. Risvanis, L. C. Balding, C. I. Johnston, and L. M. Burrell Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition Cardiovasc Res, April 1, 2002; 54(1): 51 - 57. [Abstract] [Full Text] [PDF]

				J. E. Udelson, W. B. Smith, G. H. Hendrix, C. A. Painchaud, M. Ghazzi, I. Thomas, J. K. Ghali, P. Selaru, F. Chanoine, M. L. Pressler, et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure Circulation, November 13, 2001; 104(20): 2417 - 2423. [Abstract] [Full Text] [PDF]

				Z. A. Abassi, S. Brodsky, T. Karram, I. Dobkin, J. Winaver, and A. Hoffman Temporal changes in natriuretic and antinatriuretic systems after closure of a large arteriovenous fistula Cardiovasc Res, August 15, 2001; 51(3): 567 - 576. [Abstract] [Full Text] [PDF]

				M. J. Clair, M. K. King, A. T. Goldberg, J. W. Hendrick, R. Nisato, D. M. Gay, A. E. Morrison, J. H. McElmurray III, R. S. Krombach, B. R. Bond, et al. Selective Vasopressin, Angiotensin II, or Dual Receptor Blockade with Developing Congestive Heart Failure J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 852 - 860. [Abstract] [Full Text]

				L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]

				A. Tahara, Y. Tomura, K.-I. Wada, T. Kusayama, J. Tsukada, M. Takanashi, T. Yatsu, W. Uchida, and A. Tanaka Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 301 - 308. [Abstract] [Full Text]

				A. J. Manolis, C. Olympios, M. Sifaki, S. Handanis, M. Bresnahan, I. Gavras, and H. Gavras Suppressing Sympathetic Activation in Congestive Heart Failure : A New Therapeutic Strategy Hypertension, November 1, 1995; 26(5): 719 - 724. [Abstract] [Full Text]